EZH2 and glioma: Even though there is no clinical application of epidrugs targeting glioma, azemetostat, a KMT6A (EZH2) inhibitor, was approved for the treatment of epithelioid sarcoma, making it the first approved histone ‘writer’ inhibitor and the first epidrug to treat solid tumors (311).